Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
RESEARCH TOOLSreports
Holding MDGL?
Track your performance easily
MDGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$168.25 - $368.29
Previous CloseN/A
Volume47.78K
Average Volume (3M)406.35K
Market Cap
$7.16B
Enterprise Value$3.73B
Total Cash (Recent Filing)$40.50M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Feb 26, 2025EPS Estimate
-4.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.07
Shares Outstanding21,810,408
10 Day Avg. Volume615,512
30 Day Avg. Volume406,353
Standard Deviation0.44
R-Squared0.00194
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)93.17
Price to Cash Flow (P/CF)-26.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue48.57
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.49
Forecast
1Y Price Target
$369.58Price Target Upside10.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Madrigal Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceYear-end 2024 cash reserves are reported at about $931 million, providing financial stability for future operations and expansions.
Market ExpansionRezdiffra is expected to expand into Europe, with plans to market it as the first approved treatment for MASH fibrosis in Europe, starting with Germany.
Market PerformanceRezdiffra's uptake is robust with total FY24 revenues including over 11.8k patients on therapy, which is meaningful after only three quarters.
Bears Say
Market CompetitionThe near-term launch of arguably more advantaged GLP-1s and longer-term threats from the FGF21 class could impact sentiment towards Rezdiffra.
Regulatory And Clinical RisksKey risks to the stock rating and price target include potential failure to obtain FDA or EMA approvals and possible clinical trial failures.
Reimbursement And Prescriber SupportThe reimbursement process for Rezdiffra is described as difficult by the majority of surveyed doctors, indicating potential challenges in early stages.
---
Ownership Overview
19.56% Insiders
27.43% Mutual Funds
0.07% Other Institutional Investors
38.03% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $168.25 and its highest was $368.29 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Madrigal Pharmaceuticals Inc’s market cap is $7.16B.
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Feb 26, 2025 which is in 25 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Oct 31, 2024. The company reported -$4.92 earnings per share for the quarter, beating the consensus estimate of -$6.748 by $1.828.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -4.23.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 21,810,408 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$4.92 in its last earnings report, beating expectations of -$6.748. Following the earnings report the stock price went up 20.104%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Among the largest hedge funds holding Madrigal Pharmaceuticals Inc’s share is Paulson & Co Inc. It holds Madrigal Pharmaceuticals Inc’s shares valued at 433M.
---
Madrigal Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$369.58 (10.39% Upside)
$369.58 (10.39% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 92%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 64.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.20%
12-Months-Change
Fundamentals
Return on Equity
-66.74%
Trailing 12-Months
Asset Growth
351.02%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
---
MDGL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong and promising launch of Rezdiffra with significant achievements in sales, coverage, and prescriber penetration. However, increased operational expenses and future uncertainties in gross-to-net adjustments present challenges. Overall, the sentiment is optimistic with a cautious outlook on future financial dynamics.Read More>---
MDGL Stock 12 Month Forecast
Average Price Target
$369.58
▲(10.39% Upside)
Technical Analysis
Altimmune
―
Galectin Therapeutics
―
Galmed Pharmaceuticals
―
Viking Therapeutics
―
Akero Therapeutics
―
Best Analysts Covering MDGL
1 Year
1 Year Success Rate
14/18 ratings generated profit
1 Year Average Return
+34.09%
reiterated a buy rating 20 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +34.09% per trade.
---